About this trial
Endovascular therapy (EVT) has proven to be more beneficial for patients with AIS caused by large vessel occlusions (LVO) than medical management alone. A recent meta-analysis of 5 RCTs showed that EVT significantly reduced disability at 90 days compared to medical management \[1\]. Despite its obvious benefits, patients may have neurological deterioration despite successful thrombectomy due to ischemia progression, intracranial hemorrhage, re-occlusion, or vasogenic edema. The incidence of early neurological deterioration (END) following EVT for acute stroke has been reported to be ranging from 14.1-35.2% with some studies defining END up to 7 days and some restricting the definition between 6-72 hours post thrombectomy. A small proportion of these patients, approximately 5.9-10.5%, experienced sICH following EVT. Whether END occurs due to ischemic or hemorrhagic it leads to worse outcomes.
Eligibility criteria
Qualifiers
Anterior circulation stroke including ACA, MCA or ICA stroke that underwent EVT including tandem occlusions.
Age ≥ 18 years
Disqualifiers
Difficulty in detecting the acoustic window by TCD
Pregnancy
Incarcerated patients
Trial design
Treatments tested in this trial
- TCD measurement
- TCD parameters
- Baseline characteristics
- Clinical data will be collected
- All follow-up patients receive a phone call